Other Finding — Non-Enhancing Mass
A non-enhancing mass is a solid three-dimensional space-occupying lesion identified on breast MRI that does not demonstrate enhancement on post-contrast sequences. It is distinguished from simple and complicated cysts by its solid composition and from enhancing masses by the complete absence of contrast uptake. Non-enhancing masses are identified on pre-contrast T1-weighted, T2-weighted, or other non-contrast sequences and are confirmed as non-enhancing via subtraction imaging or careful comparison of pre- and post-contrast series.
In BI-RADS v2025, non-enhancing masses are classified under Other Findings Typically Benign, reflecting their overwhelmingly benign nature.
Imaging Appearance
T1-Weighted (Pre-contrast)
- Variable signal depending on composition
- Fat-containing lesions (lipomas, hamartomas) appear hyperintense on T1
- Fibroadenomas and other solid masses are typically isointense to mildly hypointense relative to fibroglandular tissue
T2-Weighted
- Most non-enhancing solid masses demonstrate intermediate to low T2 signal
- Fibroadenomas may appear hyperintense on T2 (especially myxoid type)
- Lymph nodes typically show a hyperintense hilum on T2
- Oil cysts / fat necrosis follow fat signal on all sequences
Post-Contrast / Subtraction
- No enhancement on subtraction images — this is the defining criterion
- Subtraction imaging is essential to confirm absence of enhancement, as pre-existing T1 hyperintensity (fat, proteinaceous material, blood products) can mimic enhancement on post-contrast images alone
DWI
- Non-enhancing benign masses typically show no restricted diffusion
- ADC values are generally higher than malignant lesions
- DWI adds confidence but is not required for the diagnosis
Key Rule
- Non-enhancing solid masses are benign on MRI
- Critical exception: A biopsy-proven malignancy after neoadjuvant systemic therapy (NAC) may persist as a non-enhancing mass — complete imaging response does not equal complete pathologic response
Board Pearl
Non-enhancing mass = benign on MRI. The sole exception is a known cancer post-NAC. A complete enhancement response (no residual enhancement) has a false-negative rate of 20–40% for residual invasive disease depending on tumor subtype. Surgery is still indicated — do NOT downgrade to BI-RADS 1 based on imaging alone.
Subtraction Imaging
Subtraction images are generated by digitally subtracting the pre-contrast T1 series from the post-contrast T1 series. Only true enhancement remains visible.
- Essential to confirm absence of enhancement when a mass is T1-hyperintense at baseline
- Motion artifact between pre- and post-contrast acquisitions can produce misregistration artifact on subtraction — may simulate enhancement or mask it
- When subtraction is equivocal, review the source pre- and post-contrast images side by side
Board Pearl
Always verify non-enhancement with subtraction images. A T1-bright mass (e.g., proteinaceous cyst, fat-containing lesion) may appear “enhanced” on post-contrast images but shows no signal on subtraction — confirming benign non-enhancing status.
Differential Diagnosis
| Entity | T1 Signal | T2 Signal | Enhancement | Distinguishing Feature |
|---|---|---|---|---|
| Fibroadenoma (sclerosed/involuting) | Iso–low | Low–intermediate | None | Older patients, may calcify, well-circumscribed |
| Lipoma | High (fat) | High (fat) | None | Signal follows fat on all sequences; suppresses on fat-sat |
| Hamartoma (fibroadenolipoma) | Mixed (fat + soft tissue) | Mixed | None (or minimal) | “Breast within a breast” appearance, encapsulated |
| Oil cyst / fat necrosis | High (fat) | Variable | None (mature) | History of surgery/trauma, calcified rim |
| Intramammary lymph node | Intermediate | Hyperintense hilum | Variable (may enhance) | Reniform shape, fatty hilum, typically upper outer quadrant |
| Complicated cyst | High (proteinaceous) | Variable | None | Round/oval, imperceptible wall, no solid component |
| Post-NAC residual mass | Variable | Variable | None | Known malignancy — only exception to benign rule |
Clinical Significance and Management
- BI-RADS 2 (Benign) in the vast majority of cases — no follow-up required for classic non-enhancing solid masses
- If morphology is typical for a specific benign entity (lipoma, hamartoma, oil cyst), describe it as such
- If the mass is indeterminate on all sequences and non-enhancing, it is still assessed as benign per BI-RADS v2025
- Post-NAC context: Residual non-enhancing mass at the tumor bed does NOT exclude viable disease — correlate with pathology; BI-RADS assessment follows institutional post-treatment protocols
Board Pearl
The malignancy rate of truly non-enhancing solid masses on breast MRI is essentially 0% in the screening/diagnostic setting. Enhancement is a near-prerequisite for malignancy detection on MRI — this is why MRI has a very high negative predictive value (~97–99%) for invasive cancer.
Pitfalls
- Misregistration artifact on subtraction: Patient motion between pre- and post-contrast acquisitions creates bright/dark rims on subtraction that can simulate or obscure enhancement — always cross-reference with source images
- Slow or faint enhancement missed: Some low-grade malignancies enhance slowly or minimally — ensure adequate contrast dose, proper timing, and review early and delayed phases
- T1-bright lesion mistaken for enhancement: Proteinaceous cysts, hemorrhagic lesions, and fat-containing masses are bright on post-contrast T1 — subtraction resolves this
- Post-NAC false reassurance: Complete imaging response (no enhancement) has variable correlation with pathologic complete response (pCR), particularly poor in lobular carcinoma and luminal subtypes
- DWI false positive: Restricted diffusion in a non-enhancing mass (e.g., abscess, dense fibrosis) should not override the non-enhancing = benign rule in the absence of known malignancy
Edition Conflict
In the 5th edition BI-RADS, non-enhancing findings were less explicitly categorized. BI-RADS v2025 formally places non-enhancing masses under Other Findings Typically Benign with clearer guidance that these should be assessed as benign (BI-RADS 2), strengthening the recommendation against unnecessary biopsy or follow-up.
v2025 Updates
- Non-enhancing masses are now explicitly listed under Other Findings Typically Benign in the v2025 MRI lexicon
- Clearer language emphasizing that enhancement is a near-prerequisite for malignancy on breast MRI
- Subtraction imaging is reinforced as essential for confirming non-enhancement